. 2021 Sep 1;38(5):287–295. doi: 10.5152/balkanmedj.2021.20086
Content of this journal is licensed under a Table 2.
Adequacy Rate According to Specimen Type
| Specimen Type | No. EGFR Adequate (%) | No. ALK Adequate (%) | No. ROS1 Adequate (%) | No. PD-L1 Adequate (%) |
|---|---|---|---|---|
| Cytology | 40/44 (90.9%) | 41/43 (95.3%) | 34/37 (91.9%) | 61/66 (92.4%) |
| Small biopsy | 35/40 (87.5%) | 36/38 (94.7%) | 27/33 (81.8%) | 59/64 (92.2%) |
| Resection | 54/55 (98.2%) | 53/53 (100%) | 44/46 (95.7) | 88/90 (97.8%) |
| Total | 129/139 (92.8%) | 130/134 (97.0%) | 105/116 (90.5%) | 208/220 (94.5%) |
EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma tyrosine kinase gene; ROS1, proto-oncogene tyrosine-protein kinase 1 ROS; PD-L1, programmed cell death protein ligand-1.